TScan Therapeutics, Inc.: 1 tracked 2026 layoff event(s), 0 workers counted, highest AI score 6.
AI score 6 (80% interval 5–7) · evidence grade D · US · Pharma / Chemicals
Stated reason: On September 2, 2026, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the preclinical development of its in vivo solid tumor program and pause further enrollment in its Phase 3 ALLOHA-2 TM study of TSC-101. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 75% of the Company’s workforce (the “Strategic Reorg…
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5, role AI exposure +0.1
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.455, industry exposure 0.712, AI investment 0.0, contrary 0.0 · named roles: Nursing Assistants, Registered Nurses
Headcount basis: not disclosed
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
